Fingerprint
Dive into the research topics of 'Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
- R. K. Murthy*
- , S. Loi
- , A. Okines
- , E. Paplomata
- , E. Hamilton
- , S. A. Hurvitz
- , N. U. Lin
- , V. Borges
- , V. Abramson
- , C. Anders
- , P. L. Bedard
- , M. Oliveira
- , E. Jakobsen
- , T. Bachelot
- , S. S. Shachar
- , V. Muller
- , S. Braga
- , F. P. Duhoux
- , R. Greil
- , D. Cameron
*Corresponding author for this work
- University of Texas MD Anderson Cancer Center
- Peter Maccallum Cancer Centre
- Royal Marsden NHS Foundation Trust
- Emory University
- Sarah Cannon Research Institute
- University of California at Los Angeles
- Dana-Farber Cancer Institute
- University of Colorado Anschutz Medical Campus
- Vanderbilt University
- Duke University
- Princess Margaret Hospital
- University Hospital Vall d'Hebron
- University of Southern Denmark
- Centre Léon Bérard
- Rambam Health Care Campus Israel
- University of Hamburg
- Hospital Cuf Descobertas R. Mario Botas
- Université catholique de Louvain
- Paracelsus Private Medical University
- Edinburgh Cancer Research Centre
- University of North Carolina at Chapel Hill
- University of Nebraska Medical Center
- British Columbia Cancer
- German Breast Group
- Stanford University
- Seattle Genetics, Inc.
Research output: Contribution to journal › Article › peer-review
1066
Scopus
citations